证券代码：002262 证券简称：恩华药业 公告编号：2025-047 本公司及董事会全体成员保证公告内容真实、准确、完整，对公告的虚假记载、误导性 陈述或重大遗漏负连带责任。 特别提示： 1、本次申请回购注销的限制性股票涉及人数347人，回购注销的限制性股票共计390,209 股，占本次回购注销前总股本1,016,176,792股的比例为0.0384%。本次回购注销完成后，公 司股本总数由1,016,176,792股变更为1,015,786,583股。 2、本次申请回购注销的限制性股票的授予日期为2024年8月2日，回购价格为11.15元/ 股。 江苏恩华药业股份有限公司（以下简称"公司"）于2025年5月27日召开第七届董事会第 二次会议及第七届监事会第二次会议，于2025年6月13日召开2025年第一次临时股东大会，审 议通过了《关于回购注销部分限制性股票的议案》，本次回购注销部分限制性股票事项符合 《中华人民共和国公司法》《公司章程》《江苏恩华药业股份有限公司2024年限制性股票激 励计划（草案）》（以下简称"《激励计划》"或"本次激励计划"）等有关法律法规的规 定。截至本公告日，公司已在中国证券登记 ...

Core Insights - The article highlights the recent movements of social security funds in the stock market, revealing that five new stocks were added to their portfolio in the second quarter, alongside adjustments in existing holdings [1][2] Group 1: Social Security Fund Holdings - A total of 106 companies have disclosed their semi-annual reports, with social security funds appearing in 16 stocks [1] - In the second quarter, social security funds initiated positions in five stocks, increased holdings in five stocks, reduced holdings in five stocks, and maintained their position in one stock [1] - The stock with the highest number of social security fund holders is Su Shi Testing, with three funds listed among the top ten circulating shareholders, holding a total of 14.862 million shares, accounting for 2.94% of circulating shares [1] Group 2: New Stock Performance - Among the newly acquired stocks, Su Shi Testing has the highest holding percentage at 2.94%, followed by Enhua Pharmaceutical at 0.97%, and others like Weili Medical and Siwei Control [1][2] - In terms of share volume, Su Shi Testing leads with 14.862 million shares, followed by Enhua Pharmaceutical with 8.552 million shares and Xiangdian Co. with 8 million shares [1][2] Group 3: Financial Performance - Among the new stocks, five companies reported year-on-year net profit growth, with Siwei Control achieving the highest increase of 59.76%, followed by Su Shi Testing and Weili Medical with growth rates of 14.18% and 14.17% respectively [2]

Market Overview - The Shanghai Composite Index closed at 3608.33 points, above the annual line, with an increase of 0.70% [1] - The total trading volume of A-shares reached 1,290.701 billion yuan [1] Stocks Breaking Annual Line - A total of 40 A-shares have surpassed the annual line today, with notable stocks including: - Datang Telecom (4.33% deviation) - Xinquan Co., Ltd. (3.26% deviation) - Galaxy Electronics (3.20% deviation) [1] - Stocks with smaller deviations that just crossed the annual line include: - Huatech (0.00% deviation) - Huaxing Yuanchuang (0.00% deviation) - Guizhou Gas (0.00% deviation) [1] Top Performers - Datang Telecom: Increased by 5.18% with a turnover rate of 4.64% [1] - Xinquan Co., Ltd.: Increased by 10.00% with a turnover rate of 2.69% [1] - Galaxy Electronics: Increased by 7.30% with a turnover rate of 20.12% [1] Additional Notable Stocks - Other stocks with significant performance include: - Huafu Fashion: 3.71% increase, 2.87% turnover [1] - Xingrui Technology: 5.72% increase, 3.77% turnover [1] - China Shipbuilding: 2.79% increase, 1.75% turnover [1]

Group 1 - A new pet supplies company, Xuzhou Aizhi Jia Pet Supplies Co., Ltd., has been established with a registered capital of 1 million yuan [1] - The business scope of the new company includes internet information services, road cargo transportation (network freight), food sales, food internet sales, and veterinary drug management [1] - The company is wholly owned by Xuzhou Enhua Unified Pharmaceutical Chain Sales Co., Ltd., which is a subsidiary of Enhua Pharmaceutical (002262) [1]

Core Viewpoint - The company Enhua Pharmaceutical (002262.SZ) has made progress in the registration application for its raw material drug NH600001, which was accepted on July 29, 2025 [2] Group 1: Company Updates - The NDA (New Drug Application) for NH600001 has been submitted and is currently under review [2] - All subjects have completed the clinical trial for NH600001 emulsion injection, and data analysis is ongoing [2] - The company plans to submit the market registration application after completing the clinical summary report [2]

Core Points - Enhua Pharmaceutical (002262) announced on August 4 that the registration application for the raw material drug NH600001 was accepted on July 29, 2025 [1] - The clinical trial for NH600001 emulsion injection has completed participant recruitment, and data analysis is currently underway [1] - A summary report of the clinical trial will be submitted for the registration application upon completion [1]

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Group 1 - The core viewpoint of the report is that Pacific Securities has given a "buy" rating for Enhua Pharmaceutical (002262.SZ) based on its strong product performance and growth potential [2] - Enhua Pharmaceutical's core products are experiencing steady growth, with rapid expansion in anesthetics and neurology-related new products [2] - The company is continuously enhancing its R&D capabilities and expanding its pipeline of new drugs [2] Group 2 - The report highlights potential risks, including price reductions for some core products and the risk of regulatory tightening [2] - There are concerns regarding the market performance of new analgesic products not meeting expectations [2] - The progress of innovative drug development may not align with anticipated timelines [2]

Core Viewpoint - Enhua Pharmaceutical (002262) has shown steady growth in its core products, with a focus on expanding its new drug pipeline and enhancing research and development efforts, leading to a "buy" rating from Pacific Securities [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93% [2]. - The net profit attributable to shareholders was 700 million yuan, reflecting a year-on-year growth of 11.38% [2]. - Basic earnings per share (EPS) reached 0.69 yuan, up 11.29% year-on-year [2]. Product Growth - The company has leveraged its product differentiation advantages to achieve stable growth in mature products while rapidly promoting new products [3]. - Anesthesia products generated revenue of 1.63 billion yuan, accounting for 54.29% of total revenue, with a year-on-year growth of 7.32% [3]. - Mental health products reported revenue of 621 million yuan, representing 20.63% of total revenue, with a year-on-year increase of 4.29% [3]. - Neurology products saw significant growth, with revenue of 166 million yuan, a year-on-year increase of 107.33% [3]. Research and Development - The company invested 395 million yuan in R&D in the first half of 2025, a year-on-year increase of 23.97%, representing 13.12% of revenue [4]. - There are currently 17 innovative drug projects under development, with various clinical trial phases completed and ongoing [4]. Profit Forecast and Investment Rating - Revenue projections for 2025-2027 are 6.40 billion, 7.26 billion, and 8.24 billion yuan, with year-on-year growth rates of 12.39%, 13.34%, and 13.51% respectively [4]. - Net profit forecasts for the same period are 1.29 billion, 1.48 billion, and 1.69 billion yuan, with growth rates of 13.19%, 14.03%, and 14.56% respectively [4]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 17, 15, and 13 for 2025-2027 [4].

Core Viewpoint - The company reported a strong performance in the first half of 2025, with significant revenue and profit growth, driven by robust sales of core products and rapid growth in new products [1][2]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, reflecting a year-on-year growth of 11.38% [1] - Basic earnings per share (EPS) reached 0.69 yuan, up 11.29% year-on-year [1] Product Performance - Anesthesia products generated revenue of 1.63 billion yuan, accounting for 54.29% of total revenue, with a year-on-year growth of 7.32% [1] - Mental health products achieved revenue of 621 million yuan, representing 20.63% of total revenue, with a year-on-year increase of 4.29% [1] - Neurology products saw revenue of 166 million yuan, making up 5.51% of total revenue, with a remarkable year-on-year growth of 107.33% [1] R&D Investment - The company invested 395 million yuan in R&D in the first half of 2025, a year-on-year increase of 23.97%, representing 13.12% of total revenue [2] - There are currently 17 innovative drug projects in the pipeline, indicating a rich new drug pipeline [2] - The company has completed one Phase III clinical study and two Phase II studies, with additional studies ongoing [2] Profit Forecast - Projected operating revenues for 2025-2027 are 6.40 billion, 7.26 billion, and 8.24 billion yuan, with year-on-year growth rates of 12.39%, 13.34%, and 13.51% respectively [2] - Expected net profits for the same period are 1.29 billion, 1.48 billion, and 1.69 billion yuan, with growth rates of 13.19%, 14.03%, and 14.56% respectively [2] - EPS forecasts for 2025-2027 are 1.27, 1.45, and 1.66 yuan, with corresponding PE ratios of 17, 15, and 13 times [2]